Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

Exclusion Criteria

• •Pregnant or lactating women
• •Progressive brain metastases according to clinical or radiological criteria
• •Brain metastases without prior radiation therapy
• •Radiation therapy within the previous 4 weeks
• •Previous radiation therapy to the only measurable lesion
• •Proteinuria ≥ 500 mgr of protein daily
• •Uncontrolled hypertension
• •Documented hemorrhagic diathesis or coagulation disorder
• •Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF \< normal, ventricular arrhythmia, uncontrolled hypertension)
• •Thrombotic event within the previous 6 months
• •Concurrent use of aspirin \> 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents
• •Major surgical procedure within the previous 4 weeks
• •Presence of nonhealing wound or fracture
• •Peripheral neuropathy \> grade 2 according to the NCI CTCAE (version 3.0)
• •Any sustained chronic toxicity \> grade 2 according to the NCI CTCAE (version 3.0)
• •Uncontrolled infection
• •Any serious, uncontrolled comorbidity on the investigator's judgment
• •Other cancer within the previous 5 years, except non-melanoma skin cancer and in situ cervical cancer
• •Serious psychiatric illness